Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_assertion type Assertion NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_head.
- NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_provenance.
- NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_assertion evidence source_evidence_literature NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_provenance.
- NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_assertion SIO_000772 23307549 NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_provenance.
- NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_assertion wasDerivedFrom befree-20140225 NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_provenance.
- NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_assertion wasGeneratedBy ECO_0000203 NP731116.RAY3ctsFytGDyaqDP0_XyEzIzvHKQekbcix1nBH0a_rEc130_provenance.